HaiChuang Biotech announced the completion of a Series A financing round worth tens of millions of yuan, with Light Capital serving as the exclusive financial advisor.

Shenzhen Haichuang Biotechnology Co., Ltd. (hereinafter referred to as "Haichuang Biotech") is a national high - tech enterprise focusing on immunomedicine. It officially announced today that it has completed a Series A financing of tens of millions of RMB. This round of financing was exclusively invested by Sanze Venture Capital, and Light Source Capital served as the exclusive financial advisor. The financing funds will be used for the company's new product R & D iteration, brand building, and team expansion.

Haichuang Biotech was founded in 2020. Relying on the transformation of more than 30 years of immunological scientific research achievements from the Institute of Allergy and Immunology of Shenzhen University, it focuses on skin and gut immunity, and is committed to the R & D and industrialization of anti - aging functional skin care products, functional probiotics, and related bioactive raw materials. It aims to build a full - category layout of "cosmetics, food, medicine, and medical devices".

Based on its self - developed bioactive tracking and separation technology (BTIM), Haichuang Biotech has developed the exclusive patented ingredient HEPRO - 6A®. This ingredient has activities such as anti - photoaging, anti - glycation, anti - oxidation, anti - inflammation, anti - bacteria, and damage repair. It exerts anti - aging effects synergistically from six dimensions and has won the CIC2022 "Innovative Raw Material Award" and the "InnoCosme Awards Innovative Formula Award". Currently, the Haipunuo skin care series with HEPRO - 6A® as the core ingredient is sold through online channels such as Tmall, Douyin, and the official mini - program. Under the high - end pricing strategy, the product repurchase rate remains stable at over 60%, fully verifying its excellent product strength and market recognition.

Currently, the Chinese skin care industry is undergoing a profound transformation. Consumers are no longer satisfied with basic efficacy and are instead pursuing precise skin care solutions with scientific basis. The latest research by CBNData shows that over 70% of consumers prefer skin - type - specific care, and half of the consumers will actively study the ingredient mechanism of products. This trend indicates that skin care consumption is developing towards precision and scientificization. Against this backdrop, Haichuang Biotech's scientific research accumulation constitutes its core advantage. The company was co - founded by two senior scientists: Professor Liu Zhigang, the former deputy dean of the School of Medicine of Shenzhen University, and Professor Wang Zhiyao, a doctor of immunology from the University of Oxford, UK. The core team members have been deeply involved in cutting - edge research fields such as human microbiome, allergy mechanisms, and immunology for over 30 years, and have published more than 300 academic papers related to immunology. Over 60% of the R & D team members have a doctoral degree. They have provided professional formula development services for many well - known skin care product manufacturers and established a complete product efficacy evaluation system. In addition, the team has also provided scientific research and technical support for well - known listed pharmaceutical companies such as Kexing Pharmaceutical and Guangwei Group. The solid scientific research foundation and practical experience have provided strong technological support for the successful launch of Haichuang Biotech's self - owned brand "Haipunuo HEPROA".

In addition, Haichuang Biotech continues to promote ingredient upgrading and product innovation. The exclusive patented ingredient HEPRO - 6A® was upgraded 200 times in 2024 and officially became HEPRO - 6A PRO. The 95 Black Gold Essence with this ingredient as the core has achieved remarkable results since its launch due to its cell - level anti - aging advantage. In addition, the "Zero - Pressure Eye Cream" using the new patented ingredient HEPRO - GABA® won the "APAAACI International Science and Technology Gold Award" issued by the Asia - Pacific Allergy and Clinical Immunology Congress in 2024. The sales performance of the functional probiotic series products developed based on gut immunity technology has exceeded ten million yuan in the initial stage of launch. The medical device products for infant eczema itching care and elderly skin itching care are currently in the registration application and filing stage.

Liu Jie, the founder and R & D director of Haichuang Biotech, said: "The long - term vitality of a brand always comes from solid scientific research accumulation. Therefore, in this round of financing, we will precisely invest in two cores: one is breakthrough technological R & D, and the other is attracting and cultivating top - notch industry talents. Our goal is very clear: to continuously increase R & D investment, not only to solve the existing technological bottlenecks, but also to strive to launch benchmark products that can truly define the future of the industry. Next, we will take a more determined step on the path of scientific research and innovation, and continuously enhance the core competitiveness of the Haipunuo brand. We look forward to contributing more professional strength to the development of the Chinese health industry with fruitful results. Science should exist to create beauty, and we are practicing this with our own hands. We look forward to joining hands with our peers to create the future together."

Xia Jiazhi, a partner of Sanze Venture Capital, said: "Sanze Venture Capital has long been concerned about the integrated innovation of biotechnology and the health industry. Haichuang Biotech, based on immunomedicine, has built a complete transformation system from scientific research to products. Its core technology, the BTIM activity tracking and separation technology, and the exclusive patented ingredient HEPRO - 6A® show significant innovation and application potential. We especially value the team's profound scientific research accumulation and accurate insight into market demand, which have formed unique advantages in the fields of functional skin care and microbiome health. Haichuang Biotech's full - industrial - chain layout strategy of 'cosmetics, food, medicine, and medical devices' is highly consistent with Sanze's concept of 'value investment and long - term empowerment'. We look forward to leveraging the synergy of capital and industrial resources to help Haichuang Biotech accelerate product R & D and market expansion and become a benchmark enterprise in the field of immune anti - aging."

Hong Lei, the head of the medical department and managing director of Light Source Capital, said: "Congratulations to Haichuang Biotech on successfully completing this round of financing. Against the backdrop of the in - depth integration of global biotechnology and the beauty industry, Haichuang Biotech, based on cutting - edge scientific research, has successfully built a complete innovation system from basic research to industrial transformation. We firmly believe that with the consumption upgrade and the popularization of the concept of scientific skin care, Haichuang Biotech will become an important force driving the progress of the industry. Light Source Capital looks forward to joining hands with Haichuang Biotech to help Chinese biotechnology enterprises continue to grow on the global stage and build a more internationally competitive national brand."